Huachuang Securities has released a research report stating that it maintains a 'recommended' rating for Kotobukiya (02273.HK) and expects its adjusted net income to be 418 million yuan, 558 million yuan, and 765 million yuan, respectively, from 2024 to 2026 (compared to 365 million yuan and 477 million yuan in the previous year), with year-on-year increase of 37%, 34%, and 37%. Compared with comparable medical service companies, the company's performance growth rate is faster, and it should enjoy a certain premium valuation. Based on its adjusted net income, the company is expected to have a target PE of 30 times in 2024, corresponding to a target market cap of HKD 14 billion. The current expansion of the company's stores and internal growth are progressing steadily, and its performance is relatively certain.
华创证券：维持固生堂(02273.HK)“推荐”评级 当前业绩确定性较强
Huachuang Securities: Maintains a "Recommended" rating for GSK (02273.HK), with strong current performance certainty.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.